Business
WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced construction has begun for a new modular Drug Product (DP) facility, which will become part of the company's CRDMO hub in Singapore. Under a strategic collaboration between WuXi Biologics and Pharmadule Morimatsu, 470 modular components are being fabricated at Morimatsu's plant in Changshu City, and will be transported to Singapore's Tuas Biomedical Park for installation.
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats.","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"Finished building will be one of the world's largest modular biologics Drug Product (DP) facilities, and will enhance WuXi Biologics' leadership in end-to-end DP capabilities.","length":183,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":352,"olType":false},{"type":"text","content":"SINGAPORE, July 29, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced construction has begun for a new modular Drug Product (DP) facility, which will become part of the company's CRDMO hub in Singapore. Under a strategic collaboration between WuXi Biologics and Pharmadule Morimatsu, 470 modular components are being fabricated at Morimatsu's plant in Changshu City, and will be transported to Singapore's Tuas Biomedical Park for installation. Once complete, the building will be one of the world's largest modular biologics DP facilities, comprising approximately 30,000 square meters of space.","length":708,"tagName":"p"},{"type":"text","content":"The new facility will feature state-of-the-art manufacturing lines, centralized Quality Control (QC) labs supporting full release and stability testing, and Manufacturing Science and Technology (MSAT) labs, significantly enhancing the company's end-to-end DP services capabilities. Equipped with three pre-filled syringe (PFS) production lines and two vial production lines for both liquid and lyophilized products, it will deliver integrated DP manufacturing services — across both clinical and commercial stages — for multiple finished dosage forms. As part of WuXi Biologics' commitment to sustainability, the facility will incorporate green technologies such as solar panels, and an advanced energy monitoring and analysis system. Operations are expected to commence in 2027.","length":787,"tagName":"p"},{"type":"text","content":"In addition, the design phase is underway for a Drug Substance (DS) modular facility planned for the Singapore CRDMO hub.","length":121,"tagName":"p"},{"type":"text","content":"Dr. Chris Che...